Want to join the conversation?
$GILD said that total 2Q16 HIV and other anti-viral revenues in the US were $2.2Bil, up 11% sequentially. Genvoya, the most prescribed HIV regimen since the introduction of Atripla, had nearly double the revenue during the quarter. The company estimates that approx. 60,000-70,000 were using Truvada in 2Q16.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)